Guangzhou Pharmaceutical Research Institute

Guangzhou Pharmaceutical Research Institute (GPRI) is a prominent research and development organization and a key subsidiary of Guangzhou Baiyunshan Pharmaceutical Holdings. Founded in 1969, the institute serves as a comprehensive hub for drug innovation, specializing in Traditional Chinese Medicine (TCM) modernization, chemical drug development, and biological research. GPRI operates several high-level platforms, including a National GLP-compliant safety evaluation center and the National Canine Laboratory, which is a critical resource for preclinical animal testing in China. The institute provides a wide array of services to the pharmaceutical industry, including drug discovery, preclinical evaluation, and quality control standards development. Its portfolio includes the development of significant products such as Cefathiamidine, the first cephalosporin developed in China. GPRI is recognized as a National High-tech Enterprise and plays a vital role in the strategic R&D initiatives of the Guangzhou Pharmaceutical Group.